




The relative strengths and weaknesses of Provectus Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Provectus Biopharmaceuticals INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 3.2% points. The greatest weakness of Provectus Biopharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 166% points.

The company's Economic Capital Ratio, given in the ranking table, is 82%, being 194% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	3,442
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,701
Liabilities, Non-Current	0
Other Assets	40
Other Compr. Net Income	-0.37
Other Expenses	0
Other Liabilities	0
Other Net Income	-867
Other Revenues	0
Property and Equipment	32
Research and Development	2,608
Selling, General and Administrative Expense	2,064

Output Variable	Value in 1000 USD
Assets	3,513
Liabilities	7,701
Expenses	4,672
Revenues	0
Stockholders Equity	-4,187
Net Income	-5,540
Comprehensive Net Income	-5,540
BaseVar	8,377
ECR before LimitedLiability	-262%
Economic Capital Ratio	82%